| Q28943455 | A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3) |
| Q38673827 | An update on genomic-guided therapies for pediatric solid tumors. |
| Q35233147 | Analysis of an ankyrin-like region in Epstein Barr Virus encoded (EBV) BZLF-1 (ZEBRA) protein: implications for interactions with NF-κB and p53. |
| Q52340211 | Chromosomal Instability in Hodgkin Lymphoma: An In-Depth Review and Perspectives. |
| Q58704308 | Co-Expression of the Epstein-Barr Virus-Encoded Latent Membrane Proteins and the Pathogenesis of Classic Hodgkin Lymphoma |
| Q59357963 | Contribution of Epstein⁻Barr Virus Latent Proteins to the Pathogenesis of Classical Hodgkin Lymphoma |
| Q38596350 | Contribution of the Epstein-Barr Virus to the Pathogenesis of Hodgkin Lymphoma |
| Q38199088 | Curcuma Contra Cancer? Curcumin and Hodgkin's Lymphoma |
| Q64271133 | Evaluation of rs1957106 Polymorphism of NF-κBI in Glioblastoma Multiforme in Isfahan, Iran |
| Q39336821 | Genetic background and evolution of relapses in aggressive B-cell lymphomas. |
| Q39370671 | Genetic lesions of the TRAF3 and MAP3K14 genes in classical Hodgkin lymphoma |
| Q47125417 | Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility |
| Q34643277 | Hodgkin lymphoma |
| Q34350420 | Identification of a NFKBIA polymorphism associated with lower NFKBIA protein levels and poor survival outcomes in patients with glioblastoma multiforme |
| Q37683382 | Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma |
| Q38182355 | Mechanisms and consequences of constitutive NF-κB activation in B-cell lymphoid malignancies |
| Q35087835 | MiR-196a promotes pancreatic cancer progression by targeting nuclear factor kappa-B-inhibitor alpha |
| Q39817963 | Mutations in the genes coding for the NF-κB regulating factors IκBα and A20 are uncommon in nodular lymphocyte-predominant Hodgkin's lymphoma |
| Q54247368 | NF-κB Activation in Lymphoid Malignancies: Genetics, Signaling, and Targeted Therapy. |
| Q36839660 | NFKBIA deletion in glioblastomas |
| Q33849388 | Oncogenic activation of NF-kappaB. |
| Q33889168 | Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies |
| Q52591052 | Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. |
| Q38588503 | Prognostic Biomarkers for Hodgkin Lymphoma |
| Q33626623 | Rare occurrence of biallelic CYLD gene mutations in classical Hodgkin lymphoma |
| Q50657891 | Recurrent genetic defects in classical Hodgkin lymphoma cell lines. |
| Q36463861 | Recurrent somatic loss of TNFRSF14 in classical Hodgkin lymphoma |
| Q38975225 | Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC. |
| Q38937733 | The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias |
| Q37781972 | The Basis and Rational Use of Molecular Genetic Testing in Mature B-cell Lymphomas |
| Q34626576 | The molecular pathogenesis of Hodgkin lymphoma. |
| Q28069717 | Transcription Factors in the Cellular Response to Charged Particle Exposure |
| Q57802286 | Use of flow cytometry in the phenotypic diagnosis of hodgkin's lymphoma |
| Q61053563 | Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma |
| Q53913852 | [Classical Hodgkin lymphoma in north Anhui province of China: a clinic-pathological analysis of 56 cases]. |